Matrix Asset Advisors Inc. NY reduced its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 13.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 142,956 shares of the company’s stock after selling 21,471 shares during the quarter. AbbVie makes up approximately 3.1% of Matrix Asset Advisors Inc. NY’s portfolio, making the stock its 9th largest position. Matrix Asset Advisors Inc. NY’s holdings in AbbVie were worth $26,032,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in the stock. Vermillion & White Wealth Management Group LLC bought a new position in shares of AbbVie in the fourth quarter valued at approximately $26,000. Able Wealth Management LLC bought a new position in shares of AbbVie in the fourth quarter valued at approximately $33,000. IFS Advisors LLC bought a new position in shares of AbbVie in the first quarter valued at approximately $36,000. Ables Iannone Moore & Associates Inc. bought a new position in shares of AbbVie in the fourth quarter valued at approximately $37,000. Finally, Clarity Asset Management Inc. bought a new position in shares of AbbVie in the fourth quarter valued at approximately $42,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.
AbbVie Stock Up 0.2 %
Shares of NYSE:ABBV opened at $171.15 on Thursday. The stock has a market cap of $302.23 billion, a price-to-earnings ratio of 50.79, a PEG ratio of 2.18 and a beta of 0.60. The company has a quick ratio of 0.83, a current ratio of 0.94 and a debt-to-equity ratio of 7.93. AbbVie Inc. has a 12-month low of $130.96 and a 12-month high of $182.89. The business’s 50 day moving average is $164.27 and its 200 day moving average is $167.26.
AbbVie Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, August 15th. Shareholders of record on Monday, July 15th will be issued a dividend of $1.55 per share. This represents a $6.20 annualized dividend and a yield of 3.62%. The ex-dividend date of this dividend is Monday, July 15th. AbbVie’s dividend payout ratio is presently 183.98%.
Wall Street Analyst Weigh In
ABBV has been the topic of a number of recent research reports. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Wednesday, June 5th. BMO Capital Markets reduced their price target on shares of AbbVie from $195.00 to $180.00 and set an “outperform” rating on the stock in a research report on Monday, April 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price target on shares of AbbVie in a research report on Thursday, June 20th. Guggenheim boosted their price objective on AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a report on Friday, March 22nd. Finally, Piper Sandler boosted their price objective on AbbVie from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $179.64.
Get Our Latest Stock Analysis on ABBV
AbbVie Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Stories
- Five stocks we like better than AbbVie
- When to Sell a Stock for Profit or Loss
- Why Paychex Stock’s Dip is the Best Opportunity in Today’s Cycle
- How to Invest in Small Cap StocksÂ
- Any Pullback in Tech May Signal a Rotation into These 3 Sectors
- Most Volatile Stocks, What Investors Need to Know
- 3 Stocks to Watch: Oracle, Casey’s, FedEx Signal Big Gains
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.